Asina Journal Of Social Pharmacy

Previous Articles     Next Articles

Medical Insurance Data in China from Pharmacoeconomic Evaluation Perspective: Problems and Countermeasures

Lu Yan1, Ren Xiaoxiao2, Jia Yaozhu1, Sun Lihua1*   

  1. 1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.Becton Dickinson Medical Devices (Shanghai) Co. Ltd., Shanghai 200040, China
  • Online:2016-12-20 Published:2017-02-08
  • Contact: Sun Lihua, professor. Major research area: pharmacoeconomics, medical investment performance and management, etc. Tel: 024-23986553, E-mail: slh-3632@163.com.

Abstract: Objective To standardize the data accumulated in medical insurance database in China, make it meet pharmacoeconomic evaluation requirement so as to reduce the cost of data acquisition and improve the efficiency. Methods Literature review and field survey were used to analyze the current status and problems in medical insurance data collection in China from the requirement of pharmacoeconomic evaluation. Results and Conclusion In terms of completeness, the database lacked valid data and related information of adverse drug reactions. In terms of usability, there were problems such as chaos of disease diagnosis records and some drugs without trade names. As to data acquisition, the public did not have any permission to access the data. The data structure should be improved and the database should be standardized. At the same time, some measures should be taken to solve the problems in data transmission, to strengthen data monitoring, increase data usability, set up data application procedures and improve the efficiency of data obtaining.

Key words: pharmacoeconomics, pharmacoeconomic evaluation, medical insurance data, data acquisition, data utilization

Trendmd